Zacks Research Issues Positive Forecast for WST Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Equities researchers at Zacks Research upped their Q3 2026 EPS estimates for West Pharmaceutical Services in a research report issued on Thursday, November 13th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.95 for the quarter, up from their previous forecast of $1.82. Zacks Research has a “Hold” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2026 earnings at $1.91 EPS and Q2 2027 earnings at $2.22 EPS.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The company had revenue of $804.60 million during the quarter, compared to analysts’ expectations of $788.42 million. During the same period in the previous year, the company earned $1.85 EPS. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS.

WST has been the subject of a number of other reports. KeyCorp boosted their target price on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, October 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Tuesday, October 14th. Barclays increased their target price on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the company an “equal weight” rating in a research report on Monday, October 27th. Rothschild Redb raised shares of West Pharmaceutical Services to a “strong-buy” rating in a report on Monday, September 15th. Finally, Deutsche Bank Aktiengesellschaft set a $345.00 price target on West Pharmaceutical Services and gave the stock a “buy” rating in a research report on Friday, October 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus target price of $349.20.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $260.08 on Monday. The firm has a market cap of $18.71 billion, a price-to-earnings ratio of 38.53, a PEG ratio of 4.09 and a beta of 1.08. West Pharmaceutical Services has a 52-week low of $187.43 and a 52-week high of $348.90. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. The company’s 50 day moving average is $269.06 and its 200 day moving average is $242.69.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of hedge funds and other institutional investors have recently made changes to their positions in WST. Zions Bancorporation National Association UT acquired a new position in West Pharmaceutical Services during the first quarter worth $25,000. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services during the second quarter worth about $25,000. Quarry LP purchased a new stake in shares of West Pharmaceutical Services during the first quarter worth about $27,000. SJS Investment Consulting Inc. raised its position in shares of West Pharmaceutical Services by 1,842.9% during the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 129 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC lifted its stake in West Pharmaceutical Services by 193.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 95 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.